Immuneering has reported updated data on atebimetinib in first-line pancreatic cancer patients, linking the MEK inhibitor to ...

Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic ...

Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space ...

Over the past few years, Axsome Therapeutics has made slow and steady clinical and regulatory progress. The company's lineup ...

Pooled patients treated with TTI-101 demonstrated a 9.4% decrease from baseline in fibrosis score at week 12, compared to a 2 ...

CORA Loyalty, the loyalty portfolio arm of CORA Group ("CORA"), advises financial institutions to move beyond product-based rewards and adopt enterprise loyalty strategies that recognize and reward ...

Detailed price information for Oncolytics Biotech Inc (ONCY-Q) from The Globe and Mail including charting and trades.

InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in ...

44 th Annual J.P. Morgan Healthcare Conference Format: Company presentation Date: Thursday, January 15, 2026 Time: 12:00 PM PT Location: California East at The Westin St. Francis ...

Enanta Pharmaceuticals, Inc. , a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced updates on its research ...

First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved ...

Presented Preclinical Data: Completed IND enabling studies and shared preclinical data highlighting the unique ‘sweeper’ mechanism and product profile at the 2025 ASN Kidney Week in November and ...